CN110664818B - Medicine for treating lung cancer - Google Patents
Medicine for treating lung cancer Download PDFInfo
- Publication number
- CN110664818B CN110664818B CN201910972043.9A CN201910972043A CN110664818B CN 110664818 B CN110664818 B CN 110664818B CN 201910972043 A CN201910972043 A CN 201910972043A CN 110664818 B CN110664818 B CN 110664818B
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- clu
- cells
- trametinib
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 67
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 60
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title description 18
- 101000958332 Homo sapiens Lymphocyte antigen 6 complex locus protein G6d Proteins 0.000 claims abstract description 47
- 102100038210 Lymphocyte antigen 6 complex locus protein G6d Human genes 0.000 claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960004066 trametinib Drugs 0.000 claims abstract description 20
- 101150039781 CLU gene Proteins 0.000 claims abstract description 9
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000009458 Carcinoma in Situ Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 201000004933 in situ carcinoma Diseases 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 30
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 abstract description 13
- 108091008743 testicular receptors 4 Proteins 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 12
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000003828 downregulation Effects 0.000 abstract description 5
- 230000002950 deficient Effects 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- 238000011065 in-situ storage Methods 0.000 abstract description 3
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 58
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 102000003780 Clusterin Human genes 0.000 description 4
- 108090000197 Clusterin Proteins 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 206010069755 K-ras gene mutation Diseases 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003021 clonogenic effect Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- -1 4-ethyl-1-piperazinyl Chemical group 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 101150041972 CDKN2A gene Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- QOIOJVPRHIAONM-UHFFFAOYSA-N N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide trihydrochloride Chemical compound Cl.Cl.Cl.CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(Oc4ccnc5[nH]ccc45)c3)cc2C(F)(F)F)CC1 QOIOJVPRHIAONM-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000030716 positive regulation of phosphorylation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicament for treating lung cancer, which consists of NG25 and trametinib in a mass ratio of 4: 1; the lung cancer is lung cancer with CLU gene function loss or down regulation. Further, the lung cancer is deficient or down-regulated in CLU gene function and is induced by KRASG12DOncogene driven lung cancer. In vitro experiments show that lung cancer cells with reduced CLU knock-out are more sensitive to NG25, compared with a control, NG25 can obviously inhibit the growth of the lung cancer cells, and when the cells are treated together with Trametinib, the lung cancer cells are more obviously inhibited. Similarly, in an animal model, the TAK1 inhibitor NG25 can inhibit the growth of CLU-knocked-down cell transplanted tumors and CLU-knocked-down in-situ lung cancer, and the tumor can be remarkably atrophied by combining with the treatment of Trametinib, so that the purpose of treating the type of lung cancer is achieved.
Description
Technical Field
The invention belongs to the field of biological medicine, particularly relates to a medicine for treating lung cancer, and particularly relates to a combination of a TAK1 inhibitor NG25 and Trametinib (Trametinib) on KRAS accompanied with CLU gene function deficiencyG12DA therapeutic drug for cancer gene driven lung cancer.
Background
It is now known that the occurrence of lung cancer is mainly associated with changes in oncogenes. KRAS is a common driver gene mutation in lung cancer, with mutations in this gene being present in 10-30% of lung cancer patients. To date, there is a clinical lack of effective targeted therapies or methods for this type of lung cancer.
Although some effect of targeted therapy of lung cancer has been achieved, a significant proportion of patients still show no due therapeutic effect after taking the inhibitor against the oncogene mutated in tumors. There are many reasons for this, but the role of oncogenes is of concern. Intensive research also shows that the cancer suppressor genes have important influence on the development of lung cancer and the sensitivity of medicaments. Therefore, elucidation of the mechanism of action of oncogenes in lung cancer will help to provide an effective therapeutic strategy for the treatment of lung cancer caused by oncogene and oncogene mutations.
At present, the discovery of cancer suppressor genes of lung cancer is very limited, and besides the frequency of inactivation of the P53 gene, RB gene and CDKN2A gene in lung cancer is very high, a lot of genes with very low frequency such as SMAD2, SMAD4, TGFBR2, PTEN and the like are also discovered. In addition, low expression of some genes, such as the CLU gene, has been found to have an effect on the development of lung cancer.
The CLU gene is located on chromosome eight, contains 9 exons, and its protein Clusterin is widely distributed in tissues and is involved in a number of cellular processes, including: tissue differentiation, lipid transport, cell proliferation, apoptosis, and the like. Clusterin expression is regulated by growth factors. In addition, the protooncogenes H-Ras, c-Myc and N-Myc inhibit CLU expression. Therefore, it is considered that: inhibition of CLU expression is required for oncogene-dependent cell transformation. The study on the prostatic cancer shows that the mouse knockout of CLU can induce the generation of prostatic epithelial sarcoma (PIN), promote the cell proliferation and the enhancement of NF-kB signals, and can promote the malignant development of tumors. CLU was also found to exert a negative tumor-controlling effect in gliomas. From the Oncomine database, CLU was found to be down-regulated in mRNA levels in most primary tumors and is inversely proportional to the malignancy stage and extent of the cancer, including prostate, breast, lung. This suggests that loss of CLU function plays an important role in the development of lung cancer. However, current treatments for this type of lung cancer, even lung cancer that also simultaneously carries a KRAS mutation, lack effective treatment.
Disclosure of Invention
Based on the lack of guidance and effective treatment means aiming at CLU-deficient lung cancer, the invention aims to provide a composition for treating lung cancer. The invention constructs stable cells with reduced CLU, mouse transplantation tumor with reduced CLU and KRAS accompanied with CLU knockoutG12DAnimal models of mouse orthotopic lung cancer maximally mimic CLU-deficient lung cancers, and these models are then used to evaluate the therapeutic effect of TAK1 inhibitors on such lung cancers, and in combination with Trametinib, to treat such lung cancers that also carry KRAS mutations.
The purpose of the invention is realized by the following technical scheme:
a medicine for treating lung cancer comprises NG25(N- [4- [ (4-ethyl-1-piperazinyl) methyl ] -3- (trifluoromethyl) phenyl ] -4-methyl-3- (1H-pyrrolo [2,3-B ] pyridin-4-yloxy) benzamide) and trametinib;
preferably, in the medicament, the mass ratio of NG25 to trametinib is 4: 1;
preferably, the lung cancer is lung cancer with functional deletion or down-regulation of CLU gene;
preferably, the lung cancer is deficient or down-regulated in CLU gene function and is produced by KRASG12DOncogene driven lung cancer;
further, the lung cancer includes carcinoma in situ and transplantation carcinoma;
the medicine can also contain more than one pharmaceutically acceptable carrier; the carrier is preferably a sustained-release agent, an excipient, a filler, an adhesive, a wetting agent, a disintegrating agent, an absorption enhancer, an adsorption carrier, a surfactant or a lubricant and the like;
the medicine can be further prepared into various forms such as injection, tablets, granules or capsules, and the medicines of various formulations can be prepared according to the conventional method in the pharmaceutical field.
The invention discovers that the deletion of the CLU function can promote the activation of the TAK1 pathway, thereby activating the downstream NFKB signal and promoting the cell growth; and the inhibition of the activation of the TAK1 signal can inhibit the growth of the lung cancer cells caused by the down-regulation of Clusterin expression. These studies suggest that the TAK1 signal is a potential target for lung cancer therapy on which Clusterin downregulation depends.
N- [4- [ (4-ethyl-1-piperazinyl) methyl ] -3- (trifluoromethyl) phenyl ] -4-methyl-3- (1H-pyrrolo [2,3-B ] pyridin-4-yloxy) benzamide (NG25 trihydrochloride), NG25 for short, is a dual inhibitor of TAK1 and MAP4K 2. NG25 selectively binds to TAK1 and MAP4K2 to inhibit their activity, thereby inhibiting the activation of phosphorylation of proteins downstream thereof, such as IKK, p38 and JNK.
Compared with the prior art, the invention has the following advantages and effects:
the application discovers through a great deal of creative work: the TAK1 signaling pathway plays an important role in the growth of KRAS-mutated lung cancer with CLU loss of function, inhibition of TAK1 signaling can effectively prevent the growth of such lung cancer cells, and combination with the MEK inhibitor Trametinib can more effectively inhibit the growth of lung cancer. In vitro experiments found that lung cancer cells with reduced CLU knockdown were more sensitive to NG25, NG25 significantly inhibited lung cancer cell growth compared to controls, and when cells were co-treated with Trametinib, lung cancer cells were more significantly inhibited. Similarly, in an animal model, the TAK1 inhibitor NG25 can inhibit the growth of CLU-knocked-down cell transplanted tumors and CLU-knocked-down in-situ lung cancer, and the tumor can be remarkably atrophied by combining with the treatment of Trametinib, so that the purpose of treating the type of lung cancer is achieved.
Drawings
FIG. 1 is a graph of CLU-knockdown lung cancer cell Hop62 susceptibility to NG 25; wherein A is a protein immunoblot evaluation chart of the CLU knockdown effect of Hop62 cells; b is half inhibitory concentration (IC50) of the control group Hop62-shGFP cell to NG 25; c is half inhibitory concentration of CLU knockdown cell Hop62-shCLU to NG25 (IC 50); d is the plate clone result of the NG25 processed Hop62-shGFP and Hop62-shCLU cells, and the right is a statistical chart of the cell clone number; e is a graph of the degree of inhibition of NG25 on cell clones.
FIG. 2 is a graph showing the synergistic evaluation of NG25 and Trametinib on the inhibition of cell growth; wherein A is the result of CCK8 experiment evaluation on the growth influence of the cells of NG25 and Trametinib which are treated independently and cooperatively; b is the result of the influence of the drug and the synergistic treatment on the clone formation shown in the plate clone evaluation, and the right graph is the statistics of the cell clone number.
FIG. 3 is a graph showing the evaluation of the synergistic effect of the drugs on the growth inhibition of tumors in subcutaneous transplantable tumors in nude mice; wherein A is the recorded result of the change of the tumor size in the two-week process of the drug and the synergistic treatment; b is a comparison of tumor size taken two weeks after drug treatment, and the right is a statistical plot of tumor weight.
FIG. 4 shows LSL-KRASG12DThe inhibition effect diagram of the drugs and the synergistic treatment on the primary tumor of the lung cancer is evaluated in a lung cancer transgenic mouse model; wherein A is CT images before and after treatment of the mice; and B is a quantitative graph of the change of the tumor size after two weeks of drug treatment.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the present invention is not limited thereto.
In the following examples NG25 is an inhibitor of TAK1 and Trametinib is an inhibitor of MEK
Example 1
CLU-knockdown lung cancer cells are more sensitive to the TAK1 inhibitor NG25
First, experiment method
(1) Hop62 cell construction for stable CLU knockdown cell line construction: the expression vector pLKO.1-shCLU (Sigma, TRCN0000078611, sequence: CCGGGCTAAAGTCCTACCAGTGGAACTCGAGTTCCACTGGTAGGACTTTAGCTTTTTG) was first lentivirally packaged with 293T cells cotransformed with the viral backbone vector psPAX and PM2.G, with pLKO.1-shGFP (Sigma, SHC004) as a control. Hop62 cells were infected with the packaged shCLU and shGFP viruses, respectively, and then 2ug/mL of Puromycin was used to select cell lines stably knocked down for CLU. The knockdown effect of the cell line was evaluated by immunoblotting.
(2) The sensitivity of Hop62-shCLU cells to NG25 was examined by the method of CCK 8: adding Hop62-shGFP and Hop62-shCLU cells (800 cells/well) into a 96-well plate, treating the cells with NG25 at concentrations of 0, 0.01625, 0.3125, 0.625, 1.25, 2.5, 5 and 10 μ M for 6 days, detecting the cell activity by the method of CCK8, and finally calculating the half-inhibitory concentration of the drug to the cells by the GraphPad software (IC50)
(3) Plate colony formation assay CLU knockdown cells were evaluated for sensitivity to NG 25: 800/well of Hop62-shGFP and Hop62-shCLU cells were seeded in 6-well plates and treated with different concentrations of NG25, respectively. After 7 days of cell culture, fixation and crystal violet staining were performed, and statistics and analysis of changes in cell clone numbers were performed.
Second, experimental results and analysis
(1) CLU expression in a Hop62-shCLU stable cell line was shown to be significantly down-regulated compared to the control Hop62-shGFP by immunoblotting methods (fig. 1A).
(2) The half-inhibitory concentration of Hop62-shGFP cells on NG25 was higher than that of Hop62-shCLU cells (FIG. 1B and FIG. 1C) as detected by CCK8 cell activity, indicating that Hop62 cells are more sensitive to the drug NG25 after CLU knockdown.
(3) In the evaluation of the colony forming ability of the plate, it was found that the ability of the Hop62-shCLU cell plate clone was significantly reduced compared to the control cell under the treatment of NG25 at a concentration of 2.5. mu.M (FIG. 1D). From the analysis of the degree of drug effect, the number of shGFP clones in the control cells was reduced by 8.9%, while that in the Hop62-shCLU cells was reduced by 36.2% (FIG. 1E). These results also indicate that Hop62-shCLU cells are more sensitive to NG 25.
Example 2
NG25 synergistic with Trametinib can obviously inhibit CLU down-regulated lung cancer cell growth
First, experiment method
(1) Hop62-shCLU cells were seeded in 96-well plates at 800cells per well, and then the cells were treated with four ways of DMSO (control), NG25 (1.25. mu.M), Trametinib (Tram,25nM) and NG25 in combination with Tram (1.25. mu.M +25nM), respectively. The growth activity of the cells was measured with CCK8 every day, and the growth of the cells was plotted after 6 days.
(2) Plate clonogenic evaluation the effect of NG25 in combination with Tram on cell growth: the 6-well plates were seeded with 400 cells/well and the cells were treated with four different combinations of DMSO (control), NG25 (1.25. mu.M), Tram (25nM) and NG25 in combination with Tram (1.25. mu.M +25 nM). After 7 days of culture, cells were fixed, stained, and statistically analyzed.
Second, experimental results and analysis
(1) In the cell growth assay, NG25 slightly inhibited cell growth at this concentration treatment, and Tram had a significant inhibitory effect on cells compared to the DMSO group, whereas when the two drugs were combined, cell growth was significantly inhibited, with a significantly better effect than the treatment with the two drugs alone (fig. 2A).
(2) In a plate clone formation experiment, the single drugs of NG25 and Tram are also found to have obvious inhibition effect on the clonogenic capacity of Hop62-shCLU cells. When the two drugs act in combination, the clonogenic capacity of the cells is greatly inhibited (FIG. 2B).
Example 3
NG25 combined with Trametinib can effectively inhibit growth of CLU (CLU-downregulated lung cancer cell) subcutaneous transplantation tumor
(1) Resuspending CLU-knockdown Lung cancer cell Hop62-shCLU in BD matrixIn matrigel (3X 10 per graft tumor required)6Cell count, resuspend cells in 100 μ Ι _ BD Matrigel). The above cell and matrix mixture was inoculated into 100. mu.L each of the left and right flank of the dorsal subcutaneous skin of nude mice.
(2) After the nude mice are inoculated with the fixed tumors for about 6 days, the nude mice are divided into 4 groups, namely a blank group (no treatment), an NG25 treatment group (intraperitoneal injection, 4mg/kg/Day), a Tram treatment group (intragastric administration, 1mg/kg/Day) and a combined treatment group of NG25 and Tram (two medicaments are simultaneously administered). Hop62-shGFP was used as a control group of cells.
(3) Tumor size was measured every two days from the start of treatment according to the formula: length x width2Count size of/2. Nude mice were sacrificed 2 weeks after treatment and tumors were dissected.
Second, experimental results and analysis
Compared with the shGFP control, the Hop62-shCLU tumor grows faster and has larger tumor volume. Compared with untreated tumors, NG25 and Tram were single drugs having inhibitory effect on the growth of Hop62-shCLU tumors, whereas when NG25 and Tram were combined to treat nude mice, it was found that the growth of tumors was very significantly inhibited (fig. 3A) and the tumor volume and tumors were significantly reduced (fig. 3B).
Example 4
NG25 combined with Trametinib can effectively treat in-situ tumor
The transplanted tumor treatment model can conveniently observe and measure the size change of tumor growth in the evaluation of the drug effect, has a single system and can clearly explain the problem. But has the disadvantage of not simulating the complex canceration, tumor formation process, and interaction between tumor and stromal cells of primary lung cancer. Thus, the ability to predict treatment of a drug in a patient is poor. To this end, the present invention further utilizes LSL-KRASG12DLung cancer orthotopic tumor model of transgenic mice the therapeutic effect of NG25 in combination with Tram was evaluated.
First, experiment method
(1) About 8 weeks LSL-KRASG12DThe mouse of (2) was nasally infected with the virus of pSECC-sgCLU (the virus contains Cre, Cas9 and sgCLU, sequence: GGAGATTCAGAACGCCGTCC), and the virus was allowed to enter the mouse lung from the trachea and thenTo induce KRAS in lung epithelial cellsG12DThe activation and knocking-out of CLU gene in the cell simulates the occurrence of KRAS mutation-induced lung cancer under the condition of CLU down regulation. Mice developed lung cancer more rapidly half a year later due to CLU knockout.
(2) Computed Tomography (CT) records the size and severity of the tumor.
(3) Mice with lung cancer were divided into three groups, namely, an NG25 treatment group (intraperitoneal injection, 4mg/kg/Day), a Tram treatment group (intragastric administration, 1mg/kg/Day) and a NG25 and Tram combined treatment group (two drugs are simultaneously administered), and administration treatment was performed for 12 days. And (5) recording the change condition of the tumor size by CT detection after treatment.
Second, experimental results and analysis
After 12 days of treatment, the lung tumor status of mice in different treatment groups was scanned by CT. As a result, NG25 monotherapy resulted in a slight reduction in lung tumor area (about 38.5% reduction compared to pre-use), Tram alone resulted in a reduction of about 46.5% in tumor size, whereas NG25 combined with Tram had a very significant tumor-inhibiting effect, with a reduction of about 76.4% (fig. 4A and 4B). The therapeutic effect of the orthotopic tumor model also indicates that NG25 in combination with Tram has a significant therapeutic effect on CLU downregulated lung cancer.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (4)
1. A medicament for treating lung cancer is characterized by comprising NG25 and trametinib according to the mass ratio of 4: 1;
the structural formulas of the NG25 and the trametinib are shown as follows:
the lung cancer is CLU gene function loss orDown-regulated by KRASG12DOncogene driven lung cancers, including carcinoma in situ and transplanted cancers.
2. The medicament of claim 1, wherein: the medicine also contains more than one carrier.
3. The medicament of claim 2, wherein: the carrier is a sustained release agent, a filling agent, an adhesive, a wetting agent, a disintegrating agent, an absorption enhancer, an adsorption carrier, a surfactant or a lubricant.
4. The medicament of claim 1, wherein: the medicine is injection, tablet, granule or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910972043.9A CN110664818B (en) | 2019-10-14 | 2019-10-14 | Medicine for treating lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910972043.9A CN110664818B (en) | 2019-10-14 | 2019-10-14 | Medicine for treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110664818A CN110664818A (en) | 2020-01-10 |
| CN110664818B true CN110664818B (en) | 2021-03-19 |
Family
ID=69082124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910972043.9A Expired - Fee Related CN110664818B (en) | 2019-10-14 | 2019-10-14 | Medicine for treating lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110664818B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111358794A (en) * | 2020-03-13 | 2020-07-03 | 南通大学 | Medicine or kit for treating non-small cell lung cancer |
| CN115381822A (en) * | 2022-05-11 | 2022-11-25 | 暨南大学附属第一医院（广州华侨医院） | Medicine for treating lung cancer based on immune response activation and pharmaceutical application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011090738A2 (en) * | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
-
2019
- 2019-10-14 CN CN201910972043.9A patent/CN110664818B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011090738A2 (en) * | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| Dabrafenib and Trametinib for the Treatment of Non-Small Cell Lung Cancer;RJ Kelly等;《EXPERT REVIEW OF ANTICANCER THERAPY》;20180913;第18卷(第11期);第1063-1068页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110664818A (en) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perry et al. | Novel therapies in glioblastoma | |
| CN110664818B (en) | Medicine for treating lung cancer | |
| TW202214243A (en) | Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy | |
| TWI741731B (en) | Antitumor pharmaceutical composition comprising chidamide and use thereof | |
| CA3222772A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| CN110652514A (en) | Pharmaceutical use of third generation EGFR inhibitor | |
| WO2023142978A1 (en) | Use of cdk16 as target in preparation of medicine for treating triple-negative breast cancer | |
| CN117942345A (en) | Method for treating NUT cancer by using ARV-825 molecular ligand | |
| CN111686111B (en) | Application of MALT1 protease inhibitor in preparation of non-small cell lung cancer therapeutic drug | |
| WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
| CN111557943A (en) | Application of PD0332991 and oxitinib in preparation of drug for treating NSCLC | |
| US20220211783A1 (en) | Gmci and ddri combination therapy for treating cancer | |
| CN111450094A (en) | Application of TGF-beta receptor molecular inhibitor in pancreatic cancer treatment with cancer gene KrasG12D mutation | |
| WO2019145964A1 (en) | Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma | |
| CN110279704B (en) | Adriamycin combined medicine and application thereof | |
| US20220218801A1 (en) | Combination gmci and atri cancer treatment | |
| AU2020101830A4 (en) | Doxorubicin combined medicine and its application | |
| WO2022127788A1 (en) | Application of lenvatinib and aurora-a kinase inhibitor in preparing cancer-inhibiting drugs | |
| CN118252834B (en) | Application of vilazodone and regorafenib combined drug in treating colorectal cancer | |
| CN113069457B (en) | Combination drug for treating KRAS mutation and simultaneously myOCD dysfunction lung cancer | |
| TW202139992A (en) | A pharmaceutical combination for the treatment of a cancer | |
| US20120309847A1 (en) | Dosing regimens and methods for treating or preventing promyelocytic leukemia | |
| CN116814625A (en) | Mimic-QHSC-miRNA for preventing and/or treating hepatocellular carcinoma and application thereof | |
| Yang et al. | Sos1 deficiency ameliorates oncogenic KRAS-mediated hematopoietic stem cell exhaustion and myeloid progenitor expansion | |
| EP4247413A1 (en) | Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210319 |